CIK 1431819
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2018-Q2. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 70.39% | 1 |
| Unclassified | 29.61% | 3 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | URGN | UroGen Pharma Ltd. | Health Care | 70.39% |
| 2 | MERSANA THERAPEUTICS INC COM | Unclassified | 18.05% | |
| 3 | IMMUNE DESIGN CORP. | Unclassified | 8.06% | |
| 4 | AGILE THERAPEUTICS INC | Unclassified | 3.50% |
1/4 names classified · sector 70.4% of weight · industry 70.4% · mkt cap 70.4%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 70.4% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/2 names) · unclassified 100.0%: URGN, . Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | URGNUROGEN PHARMA LTD | 789,297 | $37M | 70.4% | HOLD |
| 2 | MERSANA THERAPEUTICS INC COM | 955,709 | $10M | 18.0% | HOLD |
| 3 | IMMUNE DESIGN CORP. | 1,236,394 | $4M | 8.1% | HOLD |
| 4 | AGILE THERAPEUTICS INC | 5,062,363 | $2M | 3.5% | HOLD |
Where this firm's principals came from and which firms its alumni went on to found.
